Grade 2: Capable of self-care; up >50% of waking hours; unable to work.
Grade 3: Limited self-care; confined to bed/chair >50% of waking hours.
Grade 4: Completely disabled; totally confined.
Grade 5: Dead.
Karnofsky Performance Status (KPS) Mapping
ECOG
KPS %
Clinical Descriptor
0
100–90
Normal activity; no evidence of disease.
1
80–70
Normal activity with effort; cares for self.
2
60–50
Requires occasional assistance; ambulatory.
3
40–30
Disabled; requires special care and assistance.
4
20–10
Very ill; hospitalization necessary; moribund.
5
0
Dead.
Section 3
Pearls/Pitfalls
Inter-Rater Reliability
Azam et al. (2019) demonstrated high inter-rater reliability across consultants, registrars, and specialist nurses.
The "Nurse Factor": Oncology nurses often provide more conservative (poorer) PS ratings than physicians because they are typically more aware of a patient’s actual social situation and level of dependence.
Scenario Complexity: PS 2 and PS 3 represent the highest degree of variability, particularly when comorbidities (e.g., Rheumatoid Arthritis) or cognitive impairments are present.
The ECOG 2 Pivot
ECOG 2 is often the "threshold" for treatment. Patients at this level have significantly higher risks of chemotherapy toxicity compared to ECOG 0-1, yet are still frequently considered for therapy.
Section 4
Next Steps
Treatment Triage
ECOG 0–1: Usually fit for standard systemic therapy and clinical trials.
ECOG 2: High risk for toxicity; consider dose reductions or single-agent therapy.
ECOG 3–4: In advanced malignancy, risks of systemic treatment often outweigh benefits; Best Supportive Care (BSC) is frequently the most appropriate path.
Section 5
Evidence Appraisal
Primary Scale Definition
Toxicity and response criteria of the Eastern Cooperative Oncology Group.
Oken MM et al. • Am J Clin Oncol. 1982;Established the standardized 0-5 criteria.
Inter-rater Validation
Performance Status Assessment by Using ECOG Score for Cancer Patients.
Azam F et al. • Case Rep Oncol. 2019;Found no significant variation in PS assessment across different oncology HCP groups.
Section 6
Literature
Historical Context
Key elements of the ECOG scale first appeared in 1960 (Zubrod et al.). It was developed by the Eastern Cooperative Oncology Group (now ECOG-ACRIN) to ensure consistency in measuring disease impact across multiple participating hospitals.
